Literature DB >> 17462572

Identification of a small-molecule inhibitor of class Ia PI3Ks with cell-based screening.

Jiong Yang1, Alykhan Shamji, Sirinya Matchacheep, Stuart L Schreiber.   

Abstract

The mammalian target of rapamycin (mTOR) signaling network is central to the regulation of cell growth in response to both growth factors and nutrients. We developed a high-throughput, cell-based assay to identify small-molecule modulators of the mTOR signaling network. One such compound, which we name quinostatin, potently inhibits this network by directly targeting the lipid-kinase activity of the catalytic subunits of class Ia PI3Ks. This study illustrates the power of unbiased, phenotypic screening as a means for illuminating cell circuitry, and resulted in the identification of a chemotype for selective inhibition of the class Ia PI3Ks.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17462572     DOI: 10.1016/j.chembiol.2007.02.004

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  8 in total

1.  Discovery of chrysoeriol, a PI3K-AKT-mTOR pathway inhibitor with potent antitumor activity against human multiple myeloma cells in vitro.

Authors:  Yang Yang; Xiaoxi Zhou; Min Xiao; Zhenya Hong; Quan Gong; Lijun Jiang; Jianfeng Zhou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-12-22

2.  Constructing and characterizing a bioactive small molecule and microRNA association network for Alzheimer's disease.

Authors:  Fanlin Meng; Enyu Dai; Xuexin Yu; Yan Zhang; Xiaowen Chen; Xinyi Liu; Shuyuan Wang; Lihua Wang; Wei Jiang
Journal:  J R Soc Interface       Date:  2013-12-18       Impact factor: 4.118

3.  Insights into the PI3-K-PKB-mTOR signalling pathway from small molecules.

Authors:  Richard M Gunn; Helen C Hailes
Journal:  J Chem Biol       Date:  2008-07-15

4.  EMUDRA: Ensemble of Multiple Drug Repositioning Approaches to improve prediction accuracy.

Authors:  Xianxiao Zhou; Minghui Wang; Igor Katsyv; Hanna Irie; Bin Zhang
Journal:  Bioinformatics       Date:  2018-09-15       Impact factor: 6.937

5.  Corynoxine, a natural autophagy enhancer, promotes the clearance of alpha-synuclein via Akt/mTOR pathway.

Authors:  Lei-Lei Chen; Ju-Xian Song; Jia-Hong Lu; Zhen-Wei Yuan; Liang-Feng Liu; Siva Sundara Kumar Durairajan; Min Li
Journal:  J Neuroimmune Pharmacol       Date:  2014-02-13       Impact factor: 4.147

6.  Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases.

Authors:  Wolfgang Link; Julen Oyarzabal; Beatriz G Serelde; Maria Isabel Albarran; Obdulia Rabal; Antonio Cebriá; Patricia Alfonso; Jesus Fominaya; Oliver Renner; Sandra Peregrina; David Soilán; Plácido A Ceballos; Ana-Isabel Hernández; Milagros Lorenzo; Paolo Pevarello; Teresa G Granda; Guido Kurz; Amancio Carnero; James R Bischoff
Journal:  J Biol Chem       Date:  2009-08-18       Impact factor: 5.157

7.  Potential therapeutic targets and small molecular drugs for pediatric B-precursor acute lymphoblastic leukemia treatment based on microarray data.

Authors:  Limei Kong; Xiaowei Zhang; Chao Li; Liping Zhou
Journal:  Oncol Lett       Date:  2017-06-08       Impact factor: 2.967

8.  Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds.

Authors:  Diego Carrella; Isabella Manni; Barbara Tumaini; Rosanna Dattilo; Federica Papaccio; Margherita Mutarelli; Francesco Sirci; Carla A Amoreo; Marcella Mottolese; Manuela Iezzi; Laura Ciolli; Valentina Aria; Roberta Bosotti; Antonella Isacchi; Fabrizio Loreni; Alberto Bardelli; Vittorio E Avvedimento; Diego di Bernardo; Luca Cardone
Journal:  Oncotarget       Date:  2016-09-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.